

RESEARCH

Open Access

Anti-malarial property of steroidal alkaloid conessine isolated from the bark of *Holarrhena antidysenterica*

Virendra K Dua^{1*}, Gaurav Verma¹, Bikram Singh², Aswathy Rajan³, Upma Bagai³, Dau Dayal Agarwal⁴, NC Gupta¹, Sandeep Kumar¹ and Ayushi Rastogi¹

Abstract

Background: In the face of chronic and emerging resistance of parasites to currently available drugs and constant need for new anti-malarials, natural plant products have been the bastion of anti-malarials for thousands of years. Moreover natural plant products and their derivatives have traditionally been a common source of drugs, and represent more than 30% of the current pharmaceutical market. The present study shows evaluation of anti-malarial effects of compound conessine isolated from plant *Holarrhena antidysenterica* frequently used against malaria in the Garhwal region of north-west Himalaya.

Methods: *In vitro* anti-plasmodial activity of compound was assessed using schizont maturation and parasite lactate dehydrogenase (pLDH) assay. Cytotoxic activities of the examined compound were determined on L-6 cells of rat skeletal muscle myoblast. The four-day test for anti-malarial activity against a chloroquine-sensitive *Plasmodium berghei* NK65 strain in BALB/c mice was used for monitoring *in vivo* activity of compound. In liver and kidney function test, the activity of alkaline phosphatase (ALP) was examined by p-NPP method, bilirubin by Jendrassik and Grof method. The urea percentage was determined by modified Berthelot method and creatinine by alkaline picrate method in serum of mice using ENZOPAK/CHEMPAK reagent kits.

Results: Compound conessine showed *in vitro* anti-plasmodial activity with its IC₅₀ value 1.9 µg/ml and 1.3 µg/ml using schizont maturation and pLDH assay respectively. The compound showed cytotoxicity IC₅₀= 14 µg/ml against L6 cells of rat skeletal muscle myoblast. The isolated compound from plant *H. antidysenterica* significantly reduced parasitaemia (at 10 mg/kg exhibited 88.95% parasite inhibition) in *P. berghei*-infected mice. Due to slightly toxic nature (cytotoxicity = 14), biochemical analysis (liver and kidney function test) of the serum from mice after administration of conessine were also observed.

Conclusion: The present investigation demonstrates that the compound conessine exhibited substantial anti-malarial property. The isolated compound could be chemically modified to obtain a more potent chemical entity with improved characteristics against malaria.

Background

Malaria is re-emerging as the world's number one killer infection, causing approximately one million deaths annually and 300–400 million infections per annum [1]. The dreaded disease is difficult to eradicate and its control is possible only with coordinated efforts of the general public, healthcare personnel and government

agencies. Dhingra and co-workers [2] challenges the World Health Organization (WHO) observation system; as per WHO more than 10 million malaria cases each year cause 15,000 deaths while based on verbal autopsy investigations between 2001 and 2003, researchers suggest that WHO figures are a huge miscalculate, and the true number is at least 125,000 deaths per year. Moreover exterior Africa, it is the profusely populated South-east Asia where 30% of the total population is approximated to be at risk of malaria, of which India contributes (80%) most of the cases [3]. The emergence

* Correspondence: vkdua51@gmail.com

¹Field Unit, Sector-3, Health Centre, BHEL, National Institute of Malaria Research, Hardwar 249403, India

Full list of author information is available at the end of the article


of drug resistance particularly to chloroquine and sulphadoxine-pyrimethamine has led to recommendations that they be replaced with artemisinin-based combination therapy (ACT) for improved efficacy. On the other hand, development of resistance to artemisinins and their associate drugs cruelly limit the utility of ACT in future. Consequently to develop alternative therapy, research on anti-malarials is urgently vital. Plants used in traditional medicines shows potential source of compounds with good anti-malarial activity [4,5]. Natural plant products and their derivatives have traditionally been a common source of drugs, and represent more than 30% of the current pharmaceutical market [6,7].

The continuing research directed towards discovery of anti-malarials from plants [8-10], it was noticed that chloroform extract of *H. antidysenterica* showed the anti-malarial properties against *Plasmodium falciparum* isolates and *P. berghei*-infected mice. Therefore, in the present investigation the anti-malarial activity of isolated principle compound conessine from *H. antidysenterica* is demonstrated against *P. falciparum* isolates and *Plasmodium berghei*-infected mice.

Methods

Collection of plants and isolation of compound

Plants and its parts were collected during flowering season of year 2008 from Cheela range of the Garhwal region and identified by Botanical Survey of India, Dehradun, India. Voucher specimens of the plants were stored in the Institute herbarium (voucher specimen number NIMRHAR-101-HA) for future reference. The compound conessine (Figure 1) was isolated from the bark of *H. antidysenterica* using the method reported earlier [11].



In vitro anti-plasmodial activity against K1 strain of *plasmodium falciparum* isolates

In vitro anti-plasmodial sensitivity of compound was assessed at National Institute of Malaria Research, New Delhi, India using Schizont maturation method [12]. Chloroquine sensitive strain FSG of *P. falciparum* derived from an Indian patient of Shahjahanpur (UP) was used for the study. Culture was maintained in A +ve erythrocytes using RPMI 1640 medium supplemented with AB Rh +ve human serum (10%), sodium bicarbonate (0.2%), HEPES buffer (25 mM) and gentamycin ($50 \mu\text{g ml}^{-1}$). The culture was treated with selected concentrations of conessine. The prepared blood smears were stained with Giemsa stain after 72 hrs of incubation % maturation of schizonts against positive control was recorded. The compound was also sent to Swiss Tropical Institute, Switzerland for screening of *in vitro* anti-plasmodial activity using the parasite lactate dehydrogenase (pLDH) assay [13]. In parasite lactate dehydrogenase (pLDH) assay, chloroquine sensitive GHA strain derived from a Ghanaian patient was used and maintained in RPMI 1640 medium supplemented with 25 mM HEPES, 0.37 mM hypoxanthine, 10% A+ve human serum together with 2-4% washed human O +ve erythrocytes and 25 mM NaHCO_3 . All cultures were conducted at $37 \pm 1^\circ\text{C}$ and an atmosphere of 3% oxygen, 4% carbon dioxide and 93% nitrogen. The sterile 384-well microtiter plates were used for performing assays, in which each well containing $2 \mu\text{l}$ of selected concentration of compound solution with $38 \mu\text{l}$ of the parasite inoculums (1% parasitaemia, 2% haematocrit). Parasite growth was compared to control wells (100% parasite growth). After 72 h of incubation at $37 \pm 1^\circ\text{C}$, plates were deep-frozen at -20°C . After thawing $5 \mu\text{l}$ from each well was transferred into another plate together with $25 \mu\text{l}$ of Malstat™ reagent and NBT (Nitro Blue Tetrazolium, 0.1 mg/ml) and $5 \mu\text{l}$ of a 1/1 mixture of PES (phenazine ethosulfate, 2 mg/ml). The plates were then kept into darkness for 2 h and the change in colour was measured with a spectrophotometer (at 655 nm). In both methods chloroquine was taken as positive control. The inhibitory concentration value, at which 50% of the parasites kill (IC_{50}) was considered for anti-plasmodial activity.

Cytotoxicity on rat skeletal muscle myoblasts (L-6 cells) and selectivity indices (SI)

The cytotoxicity of the compound was determined using reported method [14,15]. The cell line L-6, rat skeletal muscle myoblasts were seeded in 96-well Costar microtiter plates at 2×10^3 /cells/100 ml, 50 ml per well in MEM supplemented with 10% heat inactivated FBS. A three-fold serial dilution ranged from 90 to 0.13 mg/ml of compounds in test medium was added. Plates with a

final volume of 100 ml per well were incubated at 37±1°C for 72 h in a humidified incubator containing 5% CO₂ and resazurin was added as viability indicator. After an additional 2 h of incubation, the plates were measured with a fluorescence scanner using an excitation wavelength of 536 nm and an emission wavelength of 588 nm. The IC₅₀ values were calculated from the sigmoidal inhibition curves with the SoftmaxPro software.

The selectivity indices (SI) were calculated with the ratio of the IC₅₀ for the L-6 cells to the IC₅₀ for the *in vitro* anti-plasmodial activity against *P. falciparum* isolates.

In vivo anti-malarial activity against *P. Berghei*

Mouse and parasite strain

BALB/c mice (weighing 22–26 g and 4–6 weeks old) of either sex, obtained from the central animal house, Panjab University, Chandigarh were used as experimental models. They were maintained on a standard pellet diet and water *ad libitum*. *Plasmodium berghei* (NK- 65) was maintained by intraperitoneal inoculation of 1×10⁶ infected red blood cells (RBCs) to native mice [16].

Ethical clearance

The treatment of mice was according to the guidelines of committee for the purpose of control and supervision on experiments on animals (Reg No. 45/1999/CPCSEA), Panjab University, Chandigarh, India.

Drug used

Compound was dissolved in 70% Tween 80 and 30% ethanol. This solution was further diluted 10-fold with distilled water to result in a stock solution containing 7% Tween and 3% ethanol with which different concentrations of compound, i.e., 10 mg/kg, 20 mg/kg and 50 mg/kg were prepared.

Experimental design

Five groups having 10 mice each (same sex and age) were used for the present study. Groups were designated as G-1 to G-5 (Table 1). All groups were injected with

1×10⁶ *P. berghei* parasitized RBCs on day 0. One to two hours post-infection, the experimental groups were treated with a single dose of test compound. Dose of various compounds/vehicles (0.2 ml/mouse/day) were administered orally to mice of different groups for four days (day 0 to 3) according to Peters four-day test [17] 24 hours after the last treatment (day 4, i.e., day 5), Giemsa-stained blood smears were prepared from tail vein incision and percent reduction of parasite (activity) was calculated in various groups.

$$\text{Activity} = 100 - \frac{\text{Mean parasitaemia of treated}}{\text{Mean parasitaemia of control}} \times 100$$

The mean survival time (MST) of each group was calculated up to 2 weeks (14 days) post inoculation.

Liver and kidney function tests

Adverse effects due to the compound were examined by liver and kidney function tests. The activity of alkaline phosphatase (ALP) was determined by p-NPP method [18], bilirubin by Jendrassik and Grof method [19]. The urea concentration was determined using modified Berthelot method [20] and creatinine by alkaline picrate method [21] in serum of mice using ENZOPAK/CHEMPAK reagent kits (Reckon Diagnostic Pvt Ltd, Gorwa, Baroda, India). Serum was obtained from four mice of each group by centrifugation of blood at 800 g for 15 min RT. Biochemical assays were performed on day 7 in infected control and on day 10 in treated groups.

Results and discussion

Natural plant products have remained the eventual foundation for the treatment of various ailments, including malaria forever [8,10,22,23]. The chloroform extract of plant *H. antidysenterica* was found to yield considerable *in vitro* anti-malarial activity with an IC₅₀ value of 5.5 µg/ml against chloroquine-sensitive *P. falciparum* isolates, during parasite lactate dehydrogenase (pLDH) assay [9]. Therefore in the present study, the anti-malarial activity of the principal steroidal alkaloid, conessine from the stem bark of *H. antidysenterica*, was evaluated.

Table 1 Experimental groups for four-day suppressive test

Group	Drug/Vehicle
n=10	0.2 ml/mouse/day
G1	10 mg/kg
G2	20 mg/kg
G3	50 mg/kg
G4 (Vehicle control)	70% Tween 80 + 30% ethanol
G5 (Infected control)	Distilled water

All the groups was injected with 1×10⁶-infected red blood cells on day 0.
 n = number of mice in each group.

Table 2 In vitro anti-plasmodial activity of examined compound

Compound	Anti-plasmodial activity (IC ₅₀ µg/ml)		Cytotoxicity IC ₅₀ (µg/ml)	Selectivity indices	
	A	B		A	B
Conessine	1.9	1.3	14	7	10
Chloroquine	0.07	0.051	-	-	-

A: schizont maturation Method; B: pLDH method; cytotoxicity IC₅₀ (As per WHO criteria) >16 µg/ml- non cytotoxic; selectivity indices = ratio of IC₅₀ of cytotoxic activity/IC₅₀ of anti-plasmodial activity [8].

Table 3 Course of parasitaemia after inoculation of compound in different experimental groups

Group	Day 5		Day 7		MST (days)	% survival of animals on day 14
	Parasitaemia (%)	Activity (%)	Parasitaemia (%)	Activity (%)		
G1	0.8 ± 0.02	88.9	3.36 ± 2.1*	88.95	13.3	40
G2	2.15 ± 0.4	70.2	13.2 ± 2*	56.6	11.6	20
G3	2.05 ± 1	71.6	14.9 ± 3.12*	50.99	11.5	20
G4	6.6 ± 2.4	8.4	28.7 ± 4.5 ^{NS}	5.6	7	
G5	7.2 ± 1.8		30.4 ± 3.6		7.75	

Data is given as mean ± SD. Significance of values on day 7 were calculated in comparison to infected control and p-value<0.0005 is marked as *=extremely statistically significant, NS=not significant, MST=Mean Survival Time.

Conessine was isolated from the stem bark using the methods reported earlier [11]. The anti-plasmodial activity, cytotoxic activity and selectivity indices of conessine are presented in Table 2. The *in vitro* anti-plasmodial activity of conessine assessed by pLDH assay revealed more reproducible value (IC₅₀ = 1.3 µg/ml and) as compared to the activity assessed by schizont maturation method (IC₅₀ = 1.9 µg/ml). The assessed cytotoxicity of conessine against a rat cell line L-6 was found IC₅₀=14 µg/ml. While Zirihi and co-workers [24] demonstrated *in vitro* anti-plasmodial activity of conessine isolated from the plant *Funtumia elastica* against chloroquine-resistant strain FcB1 of *P. falciparum* with its IC₅₀ 1.04 µg/ml and cytotoxicity against a rat cell line L-6 with 14 µg/ml respectively. Stephenson [25] showed that conessine had no anti-malarial action in chicks infected with *Plasmodium gallinaceum*, while in the present investigation (Table 3), conessine was significantly reduce parasitaemia (Table 3) compared to the activity of the same plant chloroform extracts (70% at 30 mg/kg dose) [9] and the untreated control. It was observed that compound conessine reduce higher percentage of parasitaemia at low dose range (88.9%, at 10 mg/kg dose on day five) as compared to high dose range (reduce 71.6% of parasitaemia at 50 mg/kg dose on day five). Therefore percentage reduction of parasitaemia was further observed on day seven and was found high at low dose range (88.95%, at 10 mg/kg dose on day seven) as compared to high dose range (reduce 50.99% of parasitaemia at 50 mg/kg dose on day seven). Walker and collaborators [26] elaborated that highly potent drug evokes a larger response at low concentration that

normally occur shortly after adequate treatment doses but are not killed by suboptimal doses or by drug concentrations later on in the terminal elimination phase. Due to which the activities in all the groups were observed to decrease during the follow up period. After administration of compound conessine, the observed survival of animals (Table 3) supported for its anti-plasmodial activity compared with other steroidal alkaloids [24,27]. Due to the slightly toxic nature (cytotoxicity = 14 µg/ml), biochemical analysis (liver function tests and kidney function test) of the serum of the mice after administration of conessine was also observed and is summarized in Table 4. In terms of pathogenesis, the host liver is among the organs affected in the early stage of malaria [28] leading to significant alterations in the host hepatocyte physiology and morphology. Elevated levels of ALP and bilirubin are an indication of hepatocyte damage due to malarial infection [29]. Acute renal failure or acute kidney injury and increased levels of creatinine and urea have been also associated with severe falciparum and vivax malaria [30]. Biochemical analysis of uninfected mice administered with the compound showed that conessine affected the function of the liver and kidney significantly as compared to normal mice (Table 4). In earlier studies, chloroquine has also been reported to induce secondary increase in the certain enzymatic activities along with the increase in autophagy of cells exposed to chloroquine. Hence, this could probably justify the observed elevation in enzyme activity of liver and kidney of treated mice [31]. The administration of artemisinin is also reported to cause a significant increase in serum aspartate aminotransferase, ALP and alanine amino transferase

Table 4 Alkaline phosphatase (ALP) activity, concentration of bilirubin, urea and creatinine in different experimental groups on day 10 post inoculation of compound

Group	ALP (KA units)	Bilirubin (mg/dl)	Urea (mg/dl)	Creatinine (mg/dl)
G1	11.5±1.3 ^{NS}	1.3 ± 0.5**	160 ± 4.3**	8.55 ± 1.4**
G2	15.3 ± 1.4*	2.6 ± 0.84*	176 ± 2.8**	8.5 ± 2.2**
G3	19.2 ± 3.3**	1.3 ± 0.02**	112 ± 4.22**	10 ± 2.7**
G5	18.33 ± 2.11**	1.31 ± 0.02**	147.5 ± 2.1**	1.8 ± 0.03**
Normal mice	11 ± 2.3	1.05 ± 0.1	38.26 ± 2.6	0.83 ± 0.1

Note: Data is given as mean ± SD. Significance of values were calculated in comparison to normal control and p-value<0.005 is marked as *=very statistically significant, p-value<0.0005 **=extremely statistically significant, NS not significant.

activities [32]. The increased enzymatic activities in the study suggest that the extract might have affected the hepatic and renal indices without producing cellular necrosis. An increased level of various biochemical parameters has been reported due to administration of various anti-malarial drugs. Conessine exhibited strong anti-plasmodial activity during the course of infection as compared to the vehicle and infected control mice (Table 3). Results of the suppressive activity exhibited a good clearance rate at low concentration of 10 mg/kg (88.95%) (Table 3).

Conclusion

The steroidal alkaloid conessine isolated from the bark of *H. antidysenterica* exhibited substantial anti-malarial activity with slight cytotoxic nature. The isolated compound could be chemically modified to obtain a more potent chemical entity with improved characteristics or modified compound can become preclinical candidate against malaria.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

GV (PhD student) contributed in the laboratory work, analysis of the data and drafted the paper. VKD, BS and DDA designed the work and supervised the *in vitro* studies, analysed the data and prepared the paper. UB and AR designed and performed the *in vivo* studies as well as liver and kidney function tests. NCG, SK and AR contributed in the laboratory work. All authors contributed to the critical review of the manuscript and agree to submission.

Acknowledgements

The authors gratefully acknowledge the financial support of the Uttarakhand State Council for Science and Technology (UCOST), Dehradun, India and UNDP/WHO Special Programme for Research and Training in Tropical Diseases (TDR) for their support. Thanks are also due to Richa Bajpai for editorial assistance.

We also acknowledge the NIMR Publication Committee to approve the contents of paper.

Author details

¹Field Unit, Sector-3, Health Centre, BHEL, National Institute of Malaria Research, Hardwar 249403, India. ²Natural Plant Products Division, Institute of Himalayan Bioresource Technology, Palampur 176 061, India. ³Department of Zoology, Punjab University, Chandigarh 160014, India. ⁴School of Studies in Chemistry, Jiwaji University, Gwalior 474 011, India.

Received: 12 February 2013 Accepted: 30 May 2013

Published: 10 June 2013

References

1. WHO: *Malaria Fact sheet No. 94*. Geneva: World Health Organization; 2010. <http://www.who.int/mediacentre/factsheets/fs094/en/> (accessed 23/01/2011).
2. Dhingra N, Jha P, Sharma VP, Cohen AA, Jotkar RM, Rodriguez PS, Bassani DG, Suraweera W, Laxminarayan R, Peto R: **Adult and child malaria mortality in India: a nationally representative mortality survey.** *Lancet* 2010, **376**:1768–1774.
3. Kant R: **Global malaria burden and achieving universal coverage of interventions: a glimpse on progress and impact.** *Curr Sci* 2011, **101**:286–292.
4. Ayoola GA, Coker HAB, Adesegun SA, Adepoju-Bello AA, Obaweya K, Ezennia EC, Atangbayila TO: **Phytochemical screening and antioxidant activities of some selected medicinal plants used for malaria therapy in Southwestern Nigeria.** *Trop J Pharm Res* 2008, **7**:1019–1024.
5. Turschner S, Efferth T: **Drug resistance in Plasmodium: natural products in the fight against malaria.** *Mini Rev Med Chem* 2009, **9**:206–2124.
6. Newman DJ, Cragg GM, Snader KM: **Natural products as sources of new drugs over the period 1981–2002.** *J Nat Prod* 2003, **66**:1022–1037.
7. Njomnang Soh P, Benoit-Vical F: **Are West African plants a source of future antimalarial drugs?** *J Ethnopharmacol* 2007, **114**:130–140.
8. Dua VK, Ojha VP, Roy R, Joshi BC, Valecha N, Usha Devi C, Bhatnagar MC, Sharma VP, Subbarao SK: **Anti-malarial activity of some xanthenes isolated from the roots of *Andrographis paniculata*.** *J Ethnopharmacol* 2004, **95**:247–251.
9. Verma G, Dua VK, Agarwal DD, Atul PK: **Anti-malarial activity of *Holarrhena antidysenterica* and *Viola canescens*, plants traditionally used against malaria in the Garhwal region of north-west Himalaya.** *Malar J* 2011, **10**:20.
10. Dua VK, Verma G, Agarwal DD, Kaiser M, Brun R: **Antiprotozoal activities of traditional medicinal plants from the Garhwal region of North West Himalaya, India.** *J Ethnopharmacol* 2011, **136**:123–128.
11. Kumar N, Singh B, Bhandari P, Gupta AP, Kaul VK: **Steroidal alkaloids from *Holarrhena antidysenterica* (L.) WALL.** *Chem. Pharm Bull* 2007, **55**:912–916.
12. Trager W, Jensen JB: **Human malaria parasites in continuous culture.** *Science* 1976, **193**:673–677.
13. Makler MT, Ries JM, Williams JA, Bancroft JE, Piper RC, Gibbins BL, Hinrichs DJ: **Parasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivity.** *Am J Trop Med Hyg* 1993, **48**:738–741.
14. Page C, Page M, Noel C: **A new fluorimetric assay for cytotoxicity measurements in vitro.** *Int J Oncol* 1993, **3**:473–476.
15. Ahmed SA, Gogal RM, Walsh JE: **A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H] thymidine incorporation assay.** *J Immun Meth* 1994, **170**:211–224.
16. Santianont R: **Parasite identification, counting and staining: Application of genetic engineering techniques in tropical diseases, pathogens with special reference to plasmodia. A laboratory manual of selected techniques.** In *Proceedings of the International Laboratory workshop sponsored by the UNDP/World Bank/WHO special program for research and techniques in tropical diseases and Mahidol University, Bangkok, Thailand*. 1985:413–8.
17. Peters W: **Competitive relationship between *Eperythrozoan coccoides* and *Plasmodium berghei* in the mouse.** *Exp Parasitol* 1965, **16**:158–166.
18. German Society for Clinical Chemistry: **Standardization of methods for the estimation of enzyme activity in biological fluids.** *J Clin Chem Clin Biochem* 1972, **8**:182–192.
19. Jendrassik L, Grof P: **Vereinfachtephotometrische Methoden zur Bestimmung des Bilirubins.** *Biochem Z* 1938, **297**:81–89.
20. Henry RJ: *Clinical Chemistry, Principles and Techniques*. New York: Harper and Row; 1968:268–269.
21. Kaplan A, Szabo LL: *Clinical Chemistry: Interpretation and Techniques*. 2nd edition. Philadelphia: Lea and Febiger; 1983:138–145.
22. Simonsen HT, Nordskjold JB, Smitt UW, Nyman U, Palpu P, Joshi P, Varughese G: **In vitro screening of Indian medicinal plants for anti-plasmodial activity.** *J Ethnopharmacol* 2001, **74**:195–204.
23. Dua VK, Verma G, Dash AP: **Antiprotozoal activity of some xanthenes isolated from the roots of *andrographis paniculata*.** *Phytother Res* 2009, **23**:126–128.
24. Zirih GN, Grellier P, Guede-Guina F, Bodo B, Mambu L: **Isolation, characterization and anti-plasmodial activity of steroidal alkaloids from *Funtumia elastica* (Preuss) Stapf.** *Bioorg Med Chem Lett* 2005, **15**:2637–2640.
25. Stephenson RP: **The pharmacological properties of conessine, isoconessine and neoconessine.** *Brit J Pharmacol* 1948, **3**:237–245.
26. Walker MG, Page CP, Hoffman BF, Curtis M: *Integrated Pharmacology*. 3rd edition. St. Louis: Mosby; 2006.
27. Devkota KP, Lenta BN, Choudhary MI, Naz Q, Fekam FB, Rosenthal PJ, Sewald N: **Cholinesterase inhibiting and antiplasmodial steroidal alkaloids from *Sarcococca hookeriana*.** *Chem Pharm Bull* 2007, **55**:1397–1401.
28. Kechrid Z, Kenouz R: **Determination of alkaline phosphatase activity in patients with different zinc metabolic disorders.** *Turk J Med Sci* 2003, **33**:387–391.
29. Vallee RL, Auid DS: **Zinc coordination, function, and structure of zinc enzymes and other proteins.** *Biochem* 1990, **29**:564–567.

30. Kochhar R, Sethy PK, Sood A: **Concurrent pancreatic ductal changes in alcoholic liver disease.** *J Gastroenterology Hepatol* 2003, **18**:1067–1070.
31. Zahid A, Abidi TS: **Effect of chloroquine on liver weight of developing albino rats.** *J Pakistan Med Assoc* 2003, **53**:21–23.
32. Udobre A, Edoho EJ, Eseyin O, Etim EI: **Effect of artemisinin with folic acid on the activities of aspartate amino transferase, alanine amino transferase and alkaline phosphatase in rat.** *Asian J Biochem* 2009, **4**:55–59.

doi:10.1186/1475-2875-12-194

Cite this article as: Dua *et al.*: Anti-malarial property of steroidal alkaloid conessine isolated from the bark of *Holarthena antidysenterica*. *Malaria Journal* 2013 **12**:194.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

